deltatrials
Unknown PHASE4 INTERVENTIONAL 2-arm NCT00699465

Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage

A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)

Sponsor: University of Helsinki

Updated 7 times since 2017 Last updated: Jul 1, 2010 Started: Aug 31, 2008 Primary completion: Jul 31, 2013 Completion: Dec 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Intracerebral Hemorrhage and is currently ongoing. University of Helsinki leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

* Although it has been poorly investigated, the risk of VTE among patients with acute primary intracerebral hemorrhage is generally believed to be at least as high as among patients with ischemic stroke. * The currently available guidelines state that while low doses of subcutaneous heparin or low-molecular-weight heparin may reduce VTE, it is possible that their effect is counterbalanced by an increase in hemorrhagic complications. * It is still unclear when (if ever) low-molecular-weight-heparin should be safely initiated in ICH patients.

* Although it has been poorly investigated, the risk of VTE among patients with acute primary intracerebral hemorrhage is generally believed to be at least as high as among patients with ischemic stroke. * The currently available guidelines state that while low doses of subcutaneous heparin or low-molecular-weight heparin may reduce VTE, it is possible that their effect is counterbalanced by an increase in hemorrhagic complications. * It is still unclear when (if ever) low-molecular-weight-heparin should be safely initiated in ICH patients.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotUnknown Status~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 19 months · monthly snapshotUnknown~Jan 2026 – present · 3 months · monthly snapshotUnknown

Change History

7 versions recorded
  1. Jan 2026 — Present [monthly]

    Unknown PHASE4

  2. Sep 2024 — Present [monthly]

    Unknown PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown StatusUnknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  5. Apr 2020 — Jan 2021 [monthly]

    Unknown Status PHASE4

Show 2 earlier versions
  1. Jun 2018 — Apr 2020 [monthly]

    Unknown Status PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE4

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Helsinki
  • University of Oulu
Data source: University of Oulu

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations